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Role and regulation of MKP-1 in airway
inflammation
Seyed M. Moosavi1,2, Pavan Prabhala3,4,5 and Alaina J. Ammit1,2*
Abstract
Mitogen-activated protein kinase (MAPK) phosphatase 1 (MKP-1) is a protein with anti-inflammatory properties and
the archetypal member of the dual-specificity phosphatases (DUSPs) family that have emerged over the past decade as
playing an instrumental role in the regulation of airway inflammation. Not only does MKP-1 serve a critical role as a
negative feedback effector, controlling the extent and duration of pro-inflammatory MAPK signalling in airway cells,
upregulation of this endogenous phosphatase has also emerged as being one of the key cellular mechanism responsible
for the beneficial actions of clinically-used respiratory medicines, including β2-agonists, phosphodiesterase inhibitors and
corticosteroids. Herein, we review the role and regulation of MKP-1 in the context of airway inflammation. We initially
outline the structure and biochemistry of MKP-1 and summarise the multi-layered molecular mechanisms responsible for
MKP-1 production more generally. We then focus in on some of the key in vitro studies in cell types relevant to airway
disease that explain how MKP-1 can be regulated in airway inflammation at the transcriptional, post-translation and post-
translational level. And finally, we address some of the potential challenges with MKP-1 upregulation that need to
be explored further to fully exploit the potential of MKP-1 to repress airway inflammation in chronic respiratory disease.
Background
Airway inflammation drives pathogenesis in chronic re-
spiratory diseases such as asthma and chronic obstruct-
ive pulmonary disease (COPD). The important roles
played by mitogen-activated protein kinases (MAPK)
superfamily members (ERK (extracellular signal related
kinase), JNK (c-Jun N-terminal kinase) and p38 MAPK)
in promoting pro-inflammatory pathogenesis and disease
progression in these chronic respiratory diseases is well-
established (reviewed in [1–3]). Over the past decade or
so, many researchers around the world, including our
group, have discovered the pivotal role played by the
MAPK deactivator, MAPK phosphatase-1 (MKP-1:
NCBI official full name - dual specificity phosphatase 1
(DUSP1)) in controlling inflammation. Not only does
MKP-1 switch off inflammatory pathways by dephos-
phorylating MAPK family members at key phosphoryl-
ation sites, playing a critical negative feedback and
homeostatic function in cellular signalling, it is also one
of the significant ways in which respiratory medicines
used in asthma and COPD achieve their beneficial effects.
Our review will focus on the role and regulation of
MKP-1 in airway inflammation. We will initially outline
the structure and biochemistry of MKP-1 and summar-
ise the multi-layered molecular mechanisms responsible
for MKP-1 production more generally. We will then
focus in on some of the key in vitro studies in cell types
relevant to airway disease that explain how MKP-1 is
regulated in airway inflammation at the transcriptional,
post-transcriptional and post-translational level. We will
highlight the critical negative feedback cellular signalling
function of MKP-1 and summarise evidence that under-
scores that upregulation of MKP-1 is an important
mechanism of action for respiratory medicines. And fi-
nally, to highlight the role played by MKP-1 in the tem-
poral regulation of cytokine expression we will touch on
some more recent studies that show that even though
MKP-1 might be abundant, it might not be active due to
oxidation. These are the future research challenges that
need to be understood to fully exploit the potential of
harnessing the anti-inflammatory power of MKP-1 to re-
solve chronic respiratory disease.
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Asthma and COPD are chronic respiratory
diseases driven by inflammation
Chronic respiratory diseases such as asthma and COPD
are driven by inflammation. Corticosteroids are mainstay
anti-inflammatory therapies that are effective in the ma-
jority of people with asthma. However, significant pro-
portions of the population with asthma (5-10%) are
resistant to corticosteroids and are classified as having
severe asthma [4]. Corticosteroid insensitivity and resist-
ance is also prevalent in people with COPD (reviewed in
[5]). Chronic inflammation in the lungs of people with
COPD drives damage and long-term decline in lung
function and, unfortunately, current COPD medications
have failed to slow the accelerated rate of lung function
decline [6], even when long term studies have been
undertaken in asymptomatic subjects with early disease
[7, 8]. Thus, there is an urgent need to develop effica-
cious anti-inflammatories to prevent disease progression.
This is where corticosteroids potentially have merit;
however, corticosteroids are much less effective in
COPD than in asthma due to intrinsic corticosteroid in-
sensitivity that exists in COPD (reviewed in [5, 9]).
Improved anti-inflammatory treatments for chronic
respiratory diseases are urgently needed. To achieve this
goal, we require an in depth understanding of the mo-
lecular mechanisms responsible for repression of airway
inflammation. This knowledge is essential to allow de-
sign and development of improved and efficacious phar-
macotherapeutic strategies for treating and preventing
lung function decline in people with chronic lung dis-
ease. Upregulation of the endogenous MAPK deactiva-
tor, MKP-1, has potential. Hence, to achieve a better
understanding of the importance of MKP-1 and its regu-
latory control of MAPK-driven pro-inflammatory path-
ways, the general structure and biochemistry of these
enzymes will be summarised in next sections.
MAPK superfamily
MAPKs are protein kinases that transduce extracellular
stimuli to different types of cellular responses. Their func-
tion and regulation have been conserved throughout evo-
lution from unicellular organisms such as brewers’ yeast,
to complex species, including humans (reviewed in [10]).
MAPKs are stimulated by different mediators including
growth factors (platelet-derived growth factor (PDGF),
epidermal growth factor (EGF), and nerve growth factor
(NGF)) [11], insulin [12], thrombin [13], angiotensin II
[14], phorbol ester-type tumour promoter, Ca2+ [15], hydro-
gen peroxide [16], arachidonic acid [17], oocyte maturation
activators [18], osmotic stress [19], UV radiation [20], acti-
vators of protein kinase C [21], T-cell antigen stimulator
[22] and cytokines, including tumour necrosis factor (TNF)
and interleukin 1β (IL-1β) [23]. Some of these MAPK-
activating stimuli lead to inflammation in airway disease
and have been confirmed experimentally in preclinical
models (reviewed in [1–3]).
MAPKs are categorised into three MAPK subfamilies;
ERK, JNK and p38 MAPK. All three subfamilies carry
the sequence –TXY–, where T and Y are threonine and
tyrosine, and X is glutamate in ERK [24], proline or gly-
cine in JNK or p38 MAPK [25, 26]. The essential re-
quirement for mammalian MAPK to become activated is
phosphorylation of both of these threonine and tyrosine
residues [27]. Since MAPKs are regulated by reversible
phosphorylation, deactivation of MAPKs can also occur
via dephosphorylation at these residues. This is the role
and function of the MAPK phosphatases (MKPs). It is
important to note however, that while dual phosphoryl-
ation of MAPKs is needed for activation, removal of one
or other phosphorylation is sufficient to reduce activity
[27]. Moreover, this may be achieved by a number of
phosphatases, the majority of which are MKPs (see sem-
inal review [28]).
MKP-1
MKPs, also officially known as dual specificity phospha-
tases (DUSPs), are responsible for dephosphorylation/
deactivation of MAPKs [29–31]. MKPs dephosphorylate
threonine and tyrosine residues which are essential for
activation of the MAPKs, as described earlier [11, 26,
27]. In this manner MKPs deactivate MAPK-induced
cellular signalling and terminate the kinase cascade.
Amongst all MKPs, MKP-1 is the most widely studied
and it has been suggested that MKP-1 has the potential
to serve as a therapeutic strategy for treatment of dis-
eases driven by inflammation (reviewed in [32]).
Structure and biochemistry of MKP-1
MKP-1 is the first enzyme and the archetypal member of
the MKP/DUSP family. Lau and Nathans (1985) first iden-
tified mouse MKP-1 cDNA as an immediate early gene
induced by serum through differential hybridization
screening of a BALB/c 3 T3 cDNA library [33]. The se-
quence of mouse MKP-1 cDNA (3CH134) was reported in
1992 [34] and shown to encode a protein of ~40 kilodal-
tons. The human homolog sequence (CL100) was revealed
as an oxidative stress-induced tyrosine phosphatase gene
[35] and the DUSP1 (CL-100) gene was shown to lie on
the long arm of chromosome 5 at a band labelled 35 [36].
Up to 11 catalytically active MKPs have now been
identified in mammalian cells (reviewed by [37]); all
MKPs share a common structure comprised of a N-
terminal non-catalytic domain and a C-terminal catalytic
domain that carries the phosphatase active site sequence
(reviewed by [38]). The crystal structure of MKP-1 pro-
tein is yet to be resolved; however, due to a high shared
sequence identity with other MKPs, such as MKP-2 [39],
MKP-3 [40], and MKP-5 [41], the tertiary structure of
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MKP-1 can be predicted by homology modeling [32]. As
shown schematically in Fig. 1, MKP-1 has two cdc-25
homology domains A (CH2A) and B (CH2B) and a con-
served protein tyrosine phosphatase (PTP) catalytic site
[34, 35, 42, 43]. This conserved PTP catalytic domain
conducts dephosphorylation on both threonine and tyro-
sine residues of MAPKs; hence the name dual specificity
phosphatases (DUSPs). As shown in Fig. 1, this site is lo-
cated in the C-terminus and comprises of three amino
acids (Arg264, Asp227 and Cys258, the amino acid num-
bers correspond with the human MKP-1 sequence); this
motif being highly conserved within the MKP family. It
is noteworthy that the non-catalytic N-terminal is re-
quired for MKP-1 activation [31] contains a region
called the Kinase Activation Motif (KIM), which in-
cludes Arg53 and Arg55; two amino acids that are critic-
ally important for engaging with MAPKs and catalytic
activation of phosphatase function. There is another
docking site in MKPs which is involved in initiating
phosphorylation of Ser296/Ser323 and inducing protein
stabilization [44]. Called “Docking site for ERK, FXFP”
(DEF), DEF and Ser296/Ser323 sites are both important
due to their impact on controlling degradation of MKP-
1 through ubiquitin-mediated MKP-1 proteolysis [44,
45]. These domains are involved in post-translational
regulation of MKP-1.
Regulation of MAPK superfamily members by MKP-1
Early studies demonstrated that MKP-1 efficaciously de-
phosphorylates both JNK and p38 MAPK [46, 47]. By ti-
trating MKP-1 expression levels, Franklin et al. suggested
that p38 MAPK and JNK are the preferred substrates of
MKP-1 [30, 48]. This finding was consistent with that of
Dorfman et al. [49] who used MKP-1 knock-out mouse
embryonic fibroblasts to show that these cells have no im-
pact on ERK activation during serum stimulation. In con-
trast, Chu et al. [50] showed that when the expression
levels of MKP-1 are high, ERK, JNK and p38 MAPK can
be dephosphorylated by MKP-1. Since that time, two
decades of evidence clearly show that MKP-1 can
dephosphorylate all members of the MAPKs super-
family, although cell type and species selectivity exists
(reviewed in [37]).
MKP-1 expression is regulated at multiple levels
Human MKP-1 is a 367 amino acid protein product of
an immediate early gene [51] that is localised within the
nucleus [52]. MKP-1 expression is regulated at multiple
levels; including transcriptional, post-transcriptional and
post-translational (as detailed below). These mechanisms
allow MKP-1 protein to be rapidly, but transiently, up-
regulated. As an early example, Kwak et al. [43] stimu-
lated HeLa cells with fetal calf serum and observed a
robust increase in the expression level of MKP-1 mRNA
after 30 min, which then returns to baseline after 3 h.
The transient temporal kinetics profile of MKP-1 is due
to the fact that MKP-1 mRNA is post-transcriptionally
regulated and MKP-1 protein is degraded by the prote-
asome. These facts, coupled with the knowledge that
MKP-1 expression is regulated at multiple levels by
MAPKs themselves (especially p38 MAPK), demon-
strates an important negative feedback loop whereby
MAPKs regulate MAPK phosphatases, and visa versa.
Understanding each level of regulation (Fig. 2) offers the
potential for pharmacological perturbation.
Transcription
A number of consensus binding elements have been
demonstrated in the 5′-promoter of MKP-1. In brief, the
MKP-1 gene promoter region has been shown to contain
binding sites for a number of transcription factors; acti-
vator protein 1 (AP-1), activator protein 2 (AP-2), nu-
clear factor κB (NF-κB), specificity protein (SP-1) and
controlled amino acid treatment/binding transcription
factor and the cyclic AMP response element (CRE), E-
box, vitamin D receptor element (VDRE) and the gluco-
corticoid responsive element (GRE) [43, 53–58]. Some
of these transcriptional regulators have been implicated














Fig. 1 The structure of MKP-1. KIM is located in the NH2 terminus, between two cdc25 homology domains. The catalytic domain is located at the
carboxyl terminus. The oxidation of the catalytic Cys258 of MKP-1 protein inactivates its phosphatase activity. In the C-terminus is the DEF docking
site for MAPKs, the phosphorylation of Ser359 and Ser364 enhances protein stability, whereas Ser296/Ser323 phosphorylation is involved in the
proteasomal degradation of MKP-1
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inflammation (the CRE, NF-κB and the GRE in particu-
lar) and these will be discussed in subsequent sections.
Post-transcriptional regulation
Most of the research on post-transcriptional control of
MKP-1 expression has been performed with respect to
mRNA stability. This process represents an important
regulatory mechanism to control the amount of protein
that is translated. mRNA transcripts contain multiple re-
gions within their 3′-untranslated region (3′-UTR)
which contain adenosine uridine rich elements (ARE).
These cis-acting motifs in the ARE regulate mRNA sta-
bility and act in concert with trans-acting RNA binding
proteins to stabilise or destabilise mRNA transcripts.
Tristetraprolin (TTP: NCBI official full name – ZFP36
ring finger protein (ZFP36)) is an important RNA bind-
ing protein [59] that can destabilise mRNA transcripts
of a number of important cytokines in the context of
chronic respiratory disease (reviewed in [3]). There is a
complex interplay between MKP-1 and TTP that is
centred on temporal p38 MAPK phosphorylation. We
believe that understanding this regulatory network is
critical to allow us to discover how to resolve inflamma-
tion in chronic respiratory disease (see later for further
discussion). Other RNA binding proteins, such as HuR
and NF90, have also been shown to control the stabilisa-
tion of MKP-1 mRNA transcripts [60]. There has also
been research focusing on microRNAs and the regula-
tion of MKP-1. MicroRNAs (miR) are endogenously
expressed non-coding small RNAs that function in a
manner similar to trans-acting RNA binding proteins, in
that they are able to trigger gene silencing and transla-
tional repression by binding to the 3′-UTR of target
mRNAs [61, 62]. These miRs are numerous and can
have conflicting/counter-acting effects on MKP-1. For
example, miR-101 was shown to have an inhibitory ef-
fect on MKP-1 mRNA in macrophages [63], but miR-
708 was shown to augment MKP-1 expression via bind-
ing to the 3′-UTR of CD38 in ASM cells [64]. Further
research is required to fully reveal the impact of miR on
MKP-1 regulation and their role in chronic respiratory
disease.
Post-translational regulation
MKP-1 activity has been modulated by many types of
post-translational regulation. Phosphorylation [65], acetyl-
ation [66] and oxidation [67] have all been reported as
post-translational modifications of MKP-1 protein.
In regards to phosphorylation, MAPKs themselves im-
pact upon MKPs in a relationship that could be de-
scribed as somewhat co-dependent: that is, we know
that MKPs bind to MAPK and dephosphorylate them at
their threonine/tyrosine regions; however, the extent and
duration of the effect of MKPs can be dictated by the
interaction with MAPKs. This is due to three notable ex-
amples of post-translational regulation of the MKP-1
protein. Firstly, there is evidence that the MAPKs need
to initially dock at the KIM region found near the N-
terminal end of the MKPs, causing MKP proteins to
change their conformation and thereby stimulate their
phosphatase activity (reviewed in [68, 69]). Secondly,
Brondello et al. [44] have shown that there are two
carboxyl-terminal serine residues (Ser359/Ser364) on
MKP-1 that can be phosphorylated by ERK and alter
protein degradation kinetics of MKP-1 causing it to be-
come more stable. Thirdly, ERK was also shown to
Fig. 2 Multi-level regulation of MKP-1 expression. MKP-1 expression is regulated at three levels: transcriptional; post-transcriptional; and the post-
translational. Upon extracellular stimulation transcription factors bind to consensus sequences within the MKP-1 5′-promoter region to induce
transcription of the MKP-1 gene. Once the gene has been transcribed into mRNA, RNA binding proteins and various micro RNAs (miR) are able to
bind to the 3′-untranslated region to modulate the stability of MKP-1 mRNA transcripts. MKP-1 can also be modified at the post-translational level,
serines can be phosphorylated, lysines can be acetylated and cysteines can be oxidised, causing MKP-1 protein activity, stability and degradation
status to change. See text for abbreviations
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promote the proteasomal decay of MKP-1. To identify
the motif necessary for proteasomal degradation, trun-
cated mutants of MKP-1 were created, which eliminated
residues 1–59, effectively removing the KIM domain
[45]. It was found that the decay kinetics remained the
same, suggesting that the KIM motif was not essential to
ERK directed MKP-1 degradation via the ubiquitin pro-
teasome pathway [45, 65]. However, the DEF motif was
important and via a series of experiments utilizing point
mutations changing key serine residues to alanines it
was revealed that ERK-mediated phosphorylation of
Ser296 and Ser323 enhanced proteasomal degradation of
MKP-1 protein through docking of the Skp1/Cul1/F-box
protein Skp2 (SCFSkp2) ubiquitin-protein isopeptide E3
ligase [45].
In post-translational protein modifications beyond phos-
phorylation, Cao et al. [66] reported that MKP-1 protein
can be acetylated, and that acetylation of Lys57 within the
KIM region of MKP-1 protein enhances interaction of this
enzyme with p38 MAPK. This serves to increase MKP-1
phosphatase activity and result in decreased levels of cel-
lular phospho-p38 MAPK and suppression of the MAPK
signalling cascade. MKP-1 protein can be also oxidized
[67, 70]. This post-translational modification inactivates
the enzyme because the catalytic Cys258 within the active
site of MKP-1 protein is oxidized. The negative impact of
this modification was first demonstrated by Kamata et al.
[67], where oxidation at the cysteine residue in the cata-
lytic section of the MKP-1 enzyme induced by reactive
oxygen species resulted in protracted JNK activation.
Moreover, MAPK-mediated monocyte migration and
macrophage recruitment were increased in the presence
of oxidised MKP-1 [71] and through S-glutathionylation
(the mixed bonds that form between glutathione and cyst-
eine residues in protein), MKP-1 was deactivated as a con-
sequence of redox stress and targeted for proteasomal
degradation [72].
Role and regulation of MKP-1 in airway
inflammation
Building on the knowledge of the role, regulation and
function of MKP-1 in fundamental cell biology, harnes-
sing the power of the endogenous phosphatase MKP-1
has the potential to control inflammation in chronic re-
spiratory disease. To achieve this, we and others have fo-
cused on investigating the mechanisms responsible for
MKP-1 expression in clinically relevant models of airway
inflammation. Both in vivo and in vitro models have
been utilized, but our review aims to bring together the
knowledge gained from in vitro models of airway inflam-
mation that predominately use human airway structural
cells, primary airway smooth muscle cells and airway
epithelia (both primary and transformed cells) in par-
ticular. These preclinical research tools have been
instrumental in furthering our understanding of the mo-
lecular mechanisms regulating MKP-1 production in the
context of respiratory disease. A variety of pro-
inflammatory stimuli have been used to demonstrate the
myriad ways in which MKP-1 expression can be regu-
lated. Moreover, recent studies have also revealed that
the mechanism of action for many of the commonly-
used respiratory medicines occurs via MKP-1 upregula-
tion. These findings will be outlined in the following
sections.
MKP-1 is a negative feedback effector
Foundational studies that demonstrated the importance
of MKP-1 as an anti-inflammatory protein with clinical
relevance to airway inflammation came from the arth-
ritis field [73]; MKP-1 was shown to be anti-
inflammatory protein responsible for many of the benefi-
cial actions of glucocorticoids (corticosteroids). Most of
the early studies in the respiratory field then focused on
the ability of corticosteroid-induced MKP-1 to repress
cytokine production. Typically, airway cells were pre-
treated with corticosteroids prior to induction of cyto-
kine production with a range of stimuli. One of the
earliest studies was by Issa et al. [74], where ASM cells
were stimulated with IL-1β or TNF and the repressive
effects of the corticosteroid-induced MKP-1 on produc-
tion of the chemokine GRO-α assessed (NCBI official
full name – C-X-C motif chemokine ligand 1 (CXCL1)).
Although the focus of the paper was on the repressive
impact of the steroid dexamethasone, this publication
was one of the first to show that a pro-inflammatory
stimulus (e.g. IL-1β) rapidly (within 1 h), but transiently,
induced the production of an anti-inflammatory protein
(i.e. MKP-1). We then showed (in 2008 [75]) that TNF
also induced MKP-1 by 1 h in ASM cells. Further stud-
ies from the Newton lab in Calgary [76] in pulmonary
(A549) and bronchial airway epithelial (BEAS-2B) cells
then showed that TNF induced MKP-1 protein that
peaked at 1 h and returned to basal levels by 2 h (A549)
and 6 h (BEAS-2B), respectively. Cytomix (IL-1β, TNF,
and interferon γ) also induced the transient upregulation
of MKP-1 in A549 cells in the same report.
Since that time much has been learned about homeo-
static negative feedback mechanisms exerted by MKP-1.
By exploring the molecular mechanisms responsible for
MKP-1 protein upregulation by TNF in ASM cells, we
found that p38 MAPK is both a stimulus and target of
MKP-1 [77]. That is, MKP-1 mRNA expression and pro-
tein upregulation occurs in a p38 MAPK-dependent man-
ner [77]; however, once MKP-1 protein is expressed, it
then acts in a negative feedback manner to dephosphory-
late p38 MAPK and reduce expression of p38 MAPK-
mediated products (including MKP-1). This is, in part, the
molecular basis of transient MKP-1 upregulation and
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underscores the importance of this MAPK-deactivating
phosphatase that serves to limit the extent and duration
of MAPK signalling. Clinically, this has been shown in al-
veolar macrophages from people with severe asthma (cor-
ticosteroid resistant) where reduced induction of MKP-1
expression has been correlated with robust activation of
p38 MAPK [78].
Transcriptional regulation of MKP-1
Although a number of transcription factors have been
shown to be linked to MKP-1 expression based on the pu-
tative cis-elements demonstrated in the 5′-UTR region of
MKP-1 gene (as outlined above and in Fig. 2), the major
ones implicated in MKP-1 upregulation in airway inflam-
mation models in vitro are CRE and GRE. This is not to
say that NF-κB-mediated MKP-1 expression is unimport-
ant in this context, rather that investigations have pre-
dominately focused on the repressive effects of MKP-1 on
NF-κB-mediated cytokine production.
CRE
In their MKP-1 promoter analysis, Kwak et al. [43] dem-
onstrated that the putative cis elements that might regu-
late MKP-1 gene expression included two CRE
(positions −163 and −118 bp from the transcription start
site). CRE is activated by cAMP and numerous publica-
tions in the past decade have shown that stimuli that
increase cAMP in airway cells increase MKP-1. As eleva-
tion of intracellular cAMP in ASM cells is the mechan-
ism of action responsible for the bronchodilatory impact
of β2-adrenergic agonists on bronchospasm, this CREB-
linked transcriptional pathway has important consequences
towards understanding the molecular mechanisms respon-
sible for commonly-used respiratory medicines. This unify-
ing, cAMP-dependent, principle links a diverse range of
molecules with MKP-1 induction, including: the bioactive
sphingolipid found increased in asthmatic airways, sphingo-
sine 1-phosphate (S1P) [79–81]; the cell-permeable cAMP
elevating agent dibutyrl cAMP [79]; the adenylate cyclase
activator forskolin [79]; short (salbutamol) and long-acting
β2-agonists (LABAs: formoterol and salmeterol) [82–84];
inhibitors of phosphodiesterase 4 (PDE4) (including cilomi-
last, rolipram, piclamilast and roflumilast N-oxide), in com-
bination with formoterol [85, 86]; and prostaglandin E2
[87]. Research has conclusively shown that these molecules
all increase cAMP in airway cells and result in increased
MKP-1 production. In some investigations, CREB phos-
phorylation was also shown [79], and the cAMP-dependent
protein kinase A (PKA) pathway was implicated through
the use of non-specific pharmacological inhibitors, such as
H-89 [83], or more conclusively demonstrated via adeno-
viral expression of the PKA inhibitor, PKIα [83]. In elegant
studies, Kaur et al. [82] have used CRE-reporter constructs
in BEAS-2B cells to confirm activation of CRE-dependent
transcription in response to cAMP-elevating agents, includ-
ing β2-agonists. This was then linked to upregulation of
anti-inflammatory genes, including MKP-1, in A549 and
BEAS-2B epithelial cells. BinMahfouz et al. [88] used epi-
thelial cell models with CRE transcriptional activation to
test combined PDE3 and PDE4 inhibitors and showed su-
perior efficacy than with either inhibitor alone. Taken to-
gether, these studies show that cAMP-elevating agents
increase MKP-1.
GRE
Researchers in respiratory inflammation have built upon
the seminal studies of MKP-1 in the arthritis field, where
MKP-1 was first shown to be a novel mediator of gluco-
corticoid action (reviewed in [73]). Corticosteroid-
inducible MKP-1 expression in cells with relevance to
airway disease is now a well-established finding first dis-
covered a decade ago. In the influential review [89]
Giembycz et al. convincingly argued that understanding
the mechanistic basis of the interaction between β2-ago-
nists and corticosteroids is the “holy grail” that will drive
the development of new optimised pharmacothera-
peutics. Summarising the data published in full by Kaur
et al. [82], they showed that the clinically-used cortico-
steroids budesonide and fluticasone induced GRE-
dependent transcription in BEAS-2B cells by stably
expressing a GRE-reporter construct, and that dexa-
methasone increased MKP-1 mRNA transcription. Issa
et al. [74] were the first to show in ASM cells that
dexamethasone induced MKP-1 mRNA and protein
expression in ASM cells. We then confirmed that dexa-
methasone induced MKP-1 protein upregulation in ASM
cells [75], as did fluticasone. Dexamethasone also induced
MKP-1 in human pulmonary (A549) cells in a temporal
manner not too dissimilar to the upregulation profile in
human bronchial epithelial cells (BEAS-2B) [76]; estab-
lishing this transformed cell line as a valuable model to
explore MKP-1 (as confirmed by us in [90, 91]).
However, despite the fact that corticosteroids are
known inducers of MKP-1 expression, and steroids are
widely accepted as powerful anti-inflammatories, the
molecular mechanisms responsible for their actions, and
the role played by MKP-1, has been the subject of inten-
sive investigation. A complete discussion is outside the
scope of this review, thus the reader is recommended
several excellent reviews on this subject [92–96]. The
classical glucocorticoid responsive element (GRE) is 15
base pairs. Interrogation of the MKP-1 5′-promoter
region by Tchen et al. [57] revealed the existence of
unusual, relaxed 10 bp cis-acting element responsible for
steroid induction of the transcriptional promoter. To
explore this in the context of airway inflammation, we
conducted a sequence of MKP-1 gene promoter analyses
where we transfected ASM cells with a luciferase
Moosavi et al. Respiratory Research  (2017) 18:154 Page 6 of 12
reporter vector containing an ∼3 kb fragment of the
human MKP-1 gene promoter upstream of the transcrip-
tion initiation site (−2975 to +247 bp) and a series of 5′-
promoter deletion constructs (kindly provided by Profes-
sor Sam Okret (Karolinska Institutet, Sweden) [97]). We
showed that dexamethasone activates MKP-1 transcrip-
tion in ASM cells via a corticosteroid-responsive region
located between −1380 and −1266 bp of the human MKP-
1 promoter [83]. Notably, this is the region that contains
the relaxed GRE consensus sequence identified by Tchen
et al. [57]. Thus, for the first time, our study [83] revealed
the molecular mechanism responsible for corticosteroid-
induced MKP-1 in primary airway cells with direct rele-
vance to inflammation in chronic respiratory disease.
Post-transcriptional regulation of MKP-1
It is fair to say that most research on MKP-1 mRNA ex-
pression in airway inflammation models in vitro have fo-
cussed on the contribution of transcriptional regulation,
rather than post-transcriptional regulation. In 2012, we
conducted two studies [77, 83] that explored whether
mRNA stability was a contributor to steady state levels of
MKP-1 mRNA expression in ASM cells. Firstly, we exam-
ined whether the β2-agonist formoterol, or the corticoster-
oid dexamethasone, regulate MKP-1 mRNA expression via
post-transcriptional mechanisms in ASM cells [83]. Using
actinomycin D chase experiments and real-time RT-PCR to
measure MKP-1 mRNA degradation over time to deter-
mine the kinetics of decay, we showed that the rate of
mRNA decay was not affected by either agent [83]; sup-
porting a role for increased transcription as the predomin-
ant mechanism of action responsible for increased MKP-1
mRNA expression in ASM cells. Secondly, we examined
whether TNF increases MKP-1 expression by enhancing
mRNA stability in a p38 MAPK-dependent manner [77].
This was important because p38 MAPK is known to post-
transcriptionally regulate many important genes, especially
MKP-1 [98]. We pretreated ASM cells with vehicle or the
p38 MAPK inhibitor SB203580 for 30 min, prior to stimu-
lation with TNF for 1 h and then performed an actinomycin
D chase experiment to measure MKP-1 mRNA stability.
Intriguingly, we discovered that the p38 MAPK pathway
exerts a small, but significant, level of control on TNF-
induced MKP-1 post-transcriptional regulation in a precise
temporal manner. Since that time, the critical importance
of temporal regulation of MKP-1 (and the central role
played by p38 MAPK) towards the repression of pro-
inflammatory cytokine production has been revealed. This
will be discussed further in following sections.
Post-translational regulation
Two post-translational regulation mechanisms with im-
portance in airway inflammation are phosphorylations
(that control proteasomal degradation) and oxidation.
Proteasomal degradation of MKP-1 in airway cells is the
mechanism responsible for the transient expression of
MKP-1 protein observed in a number of studies [74–76].
To confirm this, we pretreated ASM cells with the prote-
asome inhibitor MG-132 and showed that the temporal
kinetics of MKP-1 protein upregulation was impacted and
sustained production of MKP-1 was evident [99]. Import-
antly, proteasome inhibition reduces TNF-induced inter-
leukin 6 secretion in a MKP-1 and time-dependent
manner. Moreover, cytokine arrays revealed that MG-132
represses multiple cytokines implicated in asthma [99].
These data highlight the potential of blocking proteasomal
degradation of MKP-1 as a therapeutic target in respira-
tory disease. Furthermore, since the DEF motif controls
the interaction with the E3 ligase SCFSkp2 and proteasomal
degradation of MKP-1, we have argued [32] that blocking
this interaction using novel small molecules may result in
sustained expression of MKP-1 protein.
The final post-translational modification that is of rele-
vance in the context of chronic respiratory disease is the
oxidation of MKP-1. Oxidative stress is prevalent in pa-
tients who are smokers and those who have COPD
(reviewed in [100, 101]). In this highly oxidative environ-
ment there are a lot of reactive oxygen species present
and oxidation is possible at the cysteine residues of target
proteins. MKP-1 has a cysteine located as part of its cata-
lytic triad (see Fig. 1: Cys258) and oxidation reduces
MKP-1 activity. Recent publications on the redox regula-
tion of MKP-1 have supported this assertion [71, 91, 102].
Additionally, since MKP-1 is a p38 MAPK deactivator, it
follows that oxidation would increase p38 MAPK and the
inflammatory cytokines that are triggered as a result. This
aligns with reports of increased p38 MAPK in COPD pa-
tients and patients who smoke [103]. Oxidation of MKP-1
may also be a contributing mechanism to corticosteroid
insensitivity/resistance. We have demonstrated this both
in vivo [102] and in vitro [91] where we show that even
though MKP-1 was present, it may have been inactive due
to oxidation. The impact of oxidation on MKP-1 needs to
be reversed in order to maintain anti-inflammatory phos-
phatase action. Although the impact of oxidative stress on
a number of proteins with pro-resolving roles in patho-
genesis of COPD are well recognised (e.g. transcriptional
corepressor histone deacetylase 2 and sirtuin 1 (reviewed
in [101]), the importance of the loss of MKP-1 function
due to oxidisation is currently underappreciated and war-
rants further investigation. It is highly likely that the redox
regulation of MKP-1 is linked to resistance to corticoster-
oid insensitivity/resistance.
Clinically-used respiratory medicines induce MKP-
1 in vitro and in vivo
MKP-1 expression is now recognised as one of the ways
that respiratory medicines mediate their anti-inflammatory
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benefit. This was originally highlighted by Giembycz et al.
in 2008 [89] and since that time much has been learned
about how PDE inhibitors and LABAs enhance the anti-
inflammatory effects of corticosteroids, and the contribu-
tion of MKP-1 (reviewed in [104, 105]). While some anti-
inflammatory genes are upregulated synergistically, an ele-
gant series of studies by the Newton group in Calgary show
that MKP-1 is enhanced in an additive manner [82, 88,
104–107]. We concur: we have only ever observed additive
effects on MKP-1 production when we have combined
drug classes in our in vitro studies [83, 84]. A number of
important clinical studies have also been published by the
Newton group that examine the presence of MKP-1 in hu-
man tissue and explore the molecular mechanisms respon-
sible for corticosteroid efficacy in vivo. Kelly et al. [108]
used biopsy samples from allergen-challenged asthmatic
subjects and could not detect MKP-1 expression 10 days
post-corticosteroid (budesonide) treatment; however, the
negative results may reflect the fact that MKP-1 upregula-
tion may be more involved in the initial effects of the cor-
ticosteroid. Leigh et al. [109] have conducted a large scale
microarray analysis of biopsy RNA in a randomized,
placebo-controlled crossover study where healthy male vol-
unteers inhaled placebo or budesonide; MKP-1 (aka
DUSP1) was one of the upregulated genes. Collectively,
there is a weight of evidence that proves that clinically-used
respiratory medicines induce MKP-1 in vitro and in vivo.
Challenges with MKP-1 upregulation: too much of
a good thing, it is all in the timing, or is MKP-1
not always anti-inflammatory?
On the weight of the evidence reviewed above, it appears
theoretically plausible that we could exploit the knowledge
of molecular mechanisms responsible for MKP-1 mRNA
expression and protein upregulation to increase MKP-1 in
respiratory disease settings to reduce inflammation. How-
ever, this may not be as simple a task as it sounds. It is im-
portant to take into account the level and activation status
of the other players involved in the resolution of inflam-
mation and how this may be regulated by MKP-1. One of
the most important proteins involved in the restraint of
inflammation is the destabilising mRNA binding protein,
TTP. As mentioned earlier, MKP-1 and TTP form a cyto-
kine regulatory network that is controlled by the phos-
phorylation status of p38 MAPK. The Clark laboratory at
the University of Birmingham, UK, has led the way in new
discoveries in vivo using mice deficient in MKP-1 (Dusp1
−/−) and knock-in mice expressing active TTP (Zfp36aa/
aa) and these studies underscore the importance of the
TTP-mediated anti-inflammatory network [110, 111]. In a
recent review [59], Clark and Dean provide clarity to the
cooperation between TTP and MKP-1 and the importance
of p38 MAPK phosphorylation in TTP functionality. In
collaboration [112], we have explored this regulatory
network in ASM cells and confirmed that precise tem-
poral signalling is necessary to exert TTP-dependent anti-
inflammatory control of cytokines implicated in respira-
tory disease. In brief, we have shown that TTP expression
and activity are regulated by p38 MAPK and controlled in
a temporally distinct manner by MKP-1 [112]. Thus, when
functional, TTP can curtail airway inflammation in man-
ner similar to that described for other chronic diseases
driven by inflammation (viz arthritis) [113]. But the timing
of MKP-1 upregulation is the key to whether active TTP
is present. For example, if MKP-1 suppresses p38 MAPK
to the extent that TTP is not expressed at all, theoretically
then the consequence might be similar to that described
for p38 MAPK inhibitors (reviewed in [114]); where clin-
ical trials have been disappointing perhaps due to the in-
hibition of anti-inflammatory proteins (such as TTP).
Theoretically, this could be seen as “too much of a good
thing”; that is, MKP-1 can repressed p38 MAPK to such
an extent that the anti-inflammatory proteins are inhibited
along with the pro-inflammatory proteins.
We propose that it is all in the timing and that an in
depth understanding of temporal regulation of TTP func-
tion holds the key to exploiting the potential of MKP-1 in
the future. TTP is a very adaptable molecule controlled by
phosphorylation on two key serines (Ser52 and Ser178 in
the mouse, Ser60 and Ser186 in the human orthologue)
[59]. When phosphorylated on these sites, TTP is stable
and unable to be degraded by the proteasome, but is in-
active and unable to cause mRNA decay. Intriguingly, as
noted by Smallie et al. [111] “TTP is most evident when it
is least active and most active when it is least evident”. In
support, we treated ASM cells with the steroid dexametha-
sone 1 h after TNF stimulation (so-called “therapeutic
strategy”) and showed that MKP-1 decreased p38 MAPK
phosphorylation whilst increasing abundance of the unpho-
sphorylated (active form) of TTP. It is this active form that
was responsible for cytokine repression. In addition to the
references included above, the recent work from Shah et al.
[115, 116] in airway epithelium (both primary cells and cell
lines) clearly demonstrate the negative feed-forward control
of cytokine expression by TTP and the role played by
corticosteroid-induced MKP-1. Undoubtedly, the temporal
regulation of TTP function and its control by MKP-1 has
complexities that are beyond the scope of this review, but
temporal regulation is a rich area of current research activ-
ity and the reader is alerted to an excellent recent review
by Newton et al. on this topic [117].
Finally, there are a number of reports where DUSP1, or
MAPK inhibition, is implicated in the up-regulation of
inflammatory gene expression (summarised in [117]). The
possibility exists that MKP-1 is not always anti-
inflammatory, but whether this is due to the intricacies of
DUSP1 action and impact of temporal regulation on anti-
inflammatory outcome warrants further investigation. It
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remains a possibility that some of the earlier publications
where steroids, DUSP1, or MAPK inhibition were impli-
cated in the up-regulation of inflammatory gene expres-
sion could be due to the temporal regulation that controls
glucocorticoid and cytokine crosstalk and the feed-back,
feed-forward, and co-regulatory interactions that deter-
mine repression [117].
Conclusions
To harness the power of the MAPK deactivator MKP-1 to
repress inflammation in chronic respiratory disease we
need to learn from the lessons of the past decade of pre-
clinical studies and ensure that all drug discovery pro-
grams make sure that: (i) MKP-1 is expressed; (ii) MKP-1
is active (not oxidized); (iii) MKP-1 is upregulated at the
correct time. Ensuring that we consider the off switches
that resolve inflammation, as well as the on switches that
cause inflammation, will lead to novel and advanced phar-
macotherapeutic strategies to treat chronic respiratory
disease in the future.
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